VANCOUVER, BC / ACCESSWIRE / June 17, 2024 / Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million recorded in the same quarter of 2023. This represents a growth of 4%. The revenue increase was primarily driven by a boost in sales due to promotional activities in the respiratory segment, Allerject, and sustained growth from other core products such as Redesca and Simbrinza.
MONTREAL, QUEBEC, August 30, 2022 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced the appointment of Mr. Kyle Steiger to the role of Senior Vice-President and Chief Commercial Officer (“CCO”).
Kirkland, Quebec-based Valeo Pharma will be responsible for all commercial and medical activities for ALLERJECT in Canada for an initial period of 10 years
MONTREAL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo Pharma” or the “Company”),na Canadian pharmaceutical company, is pleased to announce that in nconnection with its previously announced bought deal private placement nof convertible unsecured debentures (the “Offering”), nthe Company and Desjardins Capital Markets, as lead underwriter and solenbookrunner, together with a syndicate of underwriters (collectively, nthe “Underwriters”), have agreed to increase the size nof the Offering from $10,000,000 to $15,000,000 aggregate principal namount of convertible unsecured debentures of the Company (the “Debentures”).
MONTREAL, QUEBEC , November 3, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (“PLA”) with Alberta Minister of Health, for the listing and public reimbursement of Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapies, on the Alberta Drug Benefit list effective November 1, 2021.